These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34066318)

  • 1. Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses.
    Campbell K; Young VL; Donaldson BC; Woodall MJ; Shields NJ; Walker GF; Ward VK; Young SL
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34066318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy.
    Panasiuk M; Zimmer K; Czarnota A; Narajczyk M; Peszyńska-Sularz G; Chraniuk M; Hovhannisyan L; Żołędowska S; Nidzworski D; Żaczek AJ; Gromadzka B
    J Nanobiotechnology; 2022 Mar; 20(1):160. PubMed ID: 35351156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer.
    Jiménez-Chávez ÁJ; Nava-García BK; Bustos-Jaimes I; Moreno-Fierros L
    Immunol Lett; 2021 Nov; 239():77-87. PubMed ID: 34508790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer.
    Tegerstedt K; Franzén AV; Andreasson K; Joneberg J; Heidari S; Ramqvist T; Dalianis T
    Anticancer Res; 2005; 25(4):2601-8. PubMed ID: 16080500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functionalisation of Virus-Like Particles Enhances Antitumour Immune Responses.
    Kramer K; Al-Barwani F; Baird MA; Young VL; Larsen DS; Ward VK; Young SL
    J Immunol Res; 2019; 2019():5364632. PubMed ID: 30729137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity.
    Joe CCD; Chatterjee S; Lovrecz G; Adams TE; Thaysen-Andersen M; Walsh R; Locarnini SA; Smooker P; Netter HJ
    Vaccine; 2020 May; 38(22):3892-3901. PubMed ID: 32284273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.
    Mohsen MO; Gomes AC; Cabral-Miranda G; Krueger CC; Leoratti FM; Stein JV; Bachmann MF
    J Control Release; 2017 Apr; 251():92-100. PubMed ID: 28257987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
    Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
    Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung CD8+ T Cell Impairment Occurs during Human Metapneumovirus Infection despite Virus-Like Particle Induction of Functional CD8+ T Cells.
    Wen SC; Schuster JE; Gilchuk P; Boyd KL; Joyce S; Williams JV
    J Virol; 2015 Sep; 89(17):8713-26. PubMed ID: 26063431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy.
    Li W; Jing Z; Wang S; Li Q; Xing Y; Shi H; Li S; Hong Z
    Biomaterials; 2021 Apr; 271():120726. PubMed ID: 33636548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.
    Hyakumura M; Walsh R; Thaysen-Andersen M; Kingston NJ; La M; Lu L; Lovrecz G; Packer NH; Locarnini S; Netter HJ
    J Virol; 2015 Nov; 89(22):11312-22. PubMed ID: 26339047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice.
    Smith M; Burchell JM; Graham R; Cohen EP; Taylor-Papadimitriou J
    Immunology; 1999 Aug; 97(4):648-55. PubMed ID: 10457219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suitability of potyviral recombinant virus-like particles bearing a complete food allergen for immunotherapy vaccines.
    Pazos-Castro D; Margain C; Gonzalez-Klein Z; Amores-Borge M; Yuste-Calvo C; Garrido-Arandia M; Zurita L; Esteban V; Tome-Amat J; Diaz-Perales A; Ponz F
    Front Immunol; 2022; 13():986823. PubMed ID: 36159839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subunit Protein Vaccine Delivery System for Tuberculosis Based on Hepatitis B Virus Core VLP (HBc-VLP) Particles.
    Dhanasooraj D; Kumar RA; Mundayoor S
    Methods Mol Biol; 2016; 1404():377-392. PubMed ID: 27076312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.
    Chen D; Xia J; Tanaka Y; Chen H; Koido S; Wernet O; Mukherjee P; Gendler SJ; Kufe D; Gong J
    Immunology; 2003 Jun; 109(2):300-7. PubMed ID: 12757626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
    Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
    J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation.
    Peacey M; Wilson S; Baird MA; Ward VK
    Biotechnol Bioeng; 2007 Dec; 98(5):968-77. PubMed ID: 17546687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer.
    Feng X; Liu H; Chu X; Sun P; Huang W; Liu C; Yang X; Sun W; Bai H; Ma Y
    Acta Biomater; 2019 Dec; 100():316-325. PubMed ID: 31542504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.